1. Rabb H, Pluznick J, Noel S. The Microbiome and Acute Kidney Injury. Nephron 2018; 140 (2): 120–123. doi: 10.1159/000490392.
2. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney inter Suppl 2012; 2: 1–138.
3. Singer M, Deutschman CS, Seymour CW et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315 (8): 801–810. doi: 10.1001/jama.2016.0287.
4. Moriyama K, Nishida O. Targeting Cytokines, Pathogen-Associated Molecular Patterns, and Damage-Associated Molecular Patterns in Sepsis via Blood Purification. Int J Mol Sci 2021; 22 (16): 8882. doi: 10.3390/ijms22168882.
5. Rudd KE, Johnson SC, Agesa KM et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet 2020; 395 (10219): 200–211. doi: 10.1016/S0140-6736 (19) 32 989-7.
6. Mankowski RT, Laitano O, Darden D et al. Sepsis-Induced Myopathy and Gut Microbiome Dysbiosis: Mechanistic Links and Therapeutic Targets. Shock 2022; 57 (1): 15–23. doi: 10.1097/SHK.0000000000001843.
7. Nakano D. Septic acute kidney injury: a review of basic research. Clin Exp Nephrol 2020; 24 (12): 1091–1102. doi: 10.1007/s10157-020-01951-3.
8. Pais T, Jorge S, Lopes JA. Acute Kidney Injury in Sepsis. Int J Mol Sci 2024; 25 (11): 5924. doi: 10.3390/ijms25115924.
9. Peerapornratana S, Manrique-Caballero CL, Gómez H et al. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney Int 2019; 96 (5): 1083–1099. doi: 10.1016/j.kint.2019. 05.026.
10. Gilbert JA, Blaser MJ, Caporaso JG et al. Current understanding of the human microbiome. Nat Med 2018; 24 (4): 392–400. doi: 10.1038/nm.4517.
11. Rajilić-Stojanović M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev 2014; 38 (5): 996–1047. doi: 10.1111/1574-6976.12075.
12. Haak BW, Wiersinga WJ. The role of the gut microbiota in sepsis. Lancet Gastroenterol Hepatol 2017; 2 (2): 135–143. doi: 10.1016/ S2468-1253 (16) 30119-4.
13. Chou YT, Kan WC, Shiao CC. Acute Kidney Injury and Gut Dysbiosis: A Narrative Review Focus on Pathophysiology and Treatment. Int J Mol Sci 2022; 23 (7): 3658. doi: 10.3390/ijms23073658.
14. Zhang J, Ankawi G, Sun J et al. Gut-kidney crosstalk in septic acute kidney injury. Crit Care 2018; 22 (1): 117. doi: 10.1186/s13054-018- 2040-y.
15. O‘Connor ME, Prowle JR. Fluid Overload. Crit Care Clin 2015; 31 (4): 803–821. doi: 10.1016/ j.ccc.2015.06.013.
16. Iba T, Levy JH. Derangement of the endothelial glycocalyx in sepsis. J Thromb Haemost 2019; 17 (2): 283–294. doi: 10.1111/jth.14371.
17. Prowle JR, Kirwan CJ, Bellomo R. Fluid management for the prevention and attenuation of acute kidney injury. Nat Rev Nephrol 2014; 10 (1): 37–47. doi: 10.1038/nrneph.2013.232.
18. Lara-Prado JI, Pazos-Pérez F, Méndez-Landa CE et al. Acute Kidney Injury and Organ Dysfunction: What Is the Role of Uremic Toxins? Toxins (Basel) 2021; 13 (8): 551. doi: 10.3390/toxins13080551.
19. Lisowska-Myjak B. Uremic toxins and their effects on multiple organ systems. Nephron Clin Pract 2014; 128 (3–4): 303–311. doi: 10.1159/000369817.
20. Graboski AL, Redinbo MR. Gut-Derived Protein-Bound Uremic Toxins. Toxins (Basel) 2020; 12 (9): 590. doi: 10.3390/toxins12090590.
21. Jiang L, Sun XY, Wang SQ et al. Indoxyl sulphate-TNFa axis mediates uremic encephalopathy in rodent acute kidney injury. Acta Pharmacol Sin 2024; 45 (7): 1406–1424. doi: 10.1038/s41401-024-01251-6.
22. André C, Bennis Y, Titeca-Beauport D et al. Two rapid, accurate liquid chromatography tandem mass spectrometry methods for the quantification of seven uremic toxins: An application for describing their accumulation kinetic profile in a context of acute kidney injury. J Chromatogr B Analyt Technol Biomed Life Sci 2020; 1152: 122234. doi: 10.1016/j.jchromb.2020.122234.
23. Arrona Cardoza P, Spillane MB, Morales Marroquin E. Alzheimer‘s disease and gut microbiota: does trimethylamine N-oxide (TMAO) play a role? Nutr Rev 2022; 80 (2): 271–281. doi: 10.1093/nutrit/nuab022.
24. Gryp T, Vanholder R, Vaneechoutte M et al. p-Cresyl Sulfate. Toxins (Basel) 2017; 9 (2): 52. doi: 10.3390/toxins9020052.
25. Gupta N, Buffa JA, Roberts AB et al. Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease. Arterioscler Thromb Vasc Biol 2020; 40 (5): 1239–1255. doi: 10.1161/ATVBAHA.120. 314139.
26. Hanna MH, Segar JL, Teesch LM et al. Urinary metabolomic markers of aminoglycoside nephrotoxicity in newborn rats. Pediatr Res 2013; 73 (5): 585–591. doi: 10.1038/pr.2013.34.
27. Krupa A, Krupa MM, Pawlak K. Kynurenine Pathway-An Underestimated Factor Modulating Innate Immunity in Sepsis-Induced Acute Kidney Injury? Cells 2022; 11 (16): 2604. doi: 10.3390/cells11162604.
28. Lee J, Lee J, Kim K et al. Antibiotic-induced intestinal microbiota depletion can attenuate the acute kidney injury to chronic kidney disease transition via NADPH oxidase 2 and trimethylamine-N-oxide inhibition. Kidney Int 2024; 105 (6): 1239–1253. doi: 10.1016/ j.kint.2024.01.040.
29. Lees HJ, Swann JR, Wilson ID et al. Hippurate: the natural history of a mammalian-microbial cometabolite. J Proteome Res 2013; 12 (4): 1527–1546. doi: 10.1021/pr300900b.
30. Lekawanvijit S, Krum H. Cardiorenal syndrome: acute kidney injury secondary to cardiovascular disease and role of protein-bound uraemic toxins. J Physiol 2014; 592 (18): 3969–3983. doi: 10.1113/jphysiol.2014.273078.
31. Niwa T. Indoxyl sulfate is a nephro-vascular toxin. J Ren Nutr 2010; 20 (5 Suppl): S2–S6. doi: 10.1053/j.jrn.2010.05.002.
32. Ren Y, Wang Z, You L et al. Gut-Derived Trimethylamine N-Oxide Promotes CCR2-Mediated Macrophage Infiltration in acute kidney injury. Nephrol Dial Transplant 2024; gfae082. doi: 10.1093/ndt/gfae082.
33. Sun B, Wang X, Liu X et al. Hippuric Acid Promotes Renal Fibrosis by Disrupting Redox Homeostasis via Facilitation of NRF2-KEAP1-CUL3 Interactions in Chronic Kidney Disease. Antioxidants (Basel) 2020; 9 (9): 783. doi: 10.3390/antiox9090783.
34. Verhaar BJH, Prodan A, Nieuwdorp M et al. Gut Microbiota in Hypertension and Atherosclerosis: A Review. Nutrients 2020; 12 (10): 2982. doi: 10.3390/nu12102982.
35. Veldeman L, Vanmassenhove J, Van Biesen W et al. Evolution of protein-bound uremic toxins indoxyl sulphate and p-cresyl sulphate in acute kidney injury. Int Urol Nephrol 2019; 51 (2): 293–302. doi: 10.1007/s11255-018-2056-x.
36. Wee HN, Liu JJ, Ching J et al. The Kynurenine Pathway in Acute Kidney Injury and Chronic Kidney Disease. Am J Nephrol 2021; 52 (10–11): 771–787. doi: 10.1159/000519811.
37. Wei L, Liao P, Wu H et al. Toxicological effects of cinnabar in rats by NMR-based metabolic profiling of urine and serum. Toxicol Appl Pharmacol 2008; 227 (3): 417–429. doi: 10.1016/ j.taap.2007.11.015.
38. Zhang J, Zhu P, Li S et al. From heart failure and kidney dysfunction to cardiorenal syndrome: TMAO may be a bridge. Front Pharmacol 2023; 14: 1291922. doi: 10.3389/fphar.2023.12 91922.
39. Zhang Y, Wang Y, Ke B et al. TMAO: how gut microbiota contributes to heart failure. Transl Res 2021; 228: 109–125. doi: 10.1016/ j.trsl.2020.08.007.
40. Gong J, Noel S, Pluznick JL et al. Gut Microbiota-Kidney Cross-Talk in Acute Kidney Injury. Semin Nephrol 2019; 39 (1): 107–116. doi: 10.1016/j.semnephrol.2018.10.009.
41. Garron ML, Henrissat B. The continuing expansion of CAZymes and their families. Curr Opin Chem Biol 2019; 53: 82–87. doi: 10.1016/ j.cbpa.2019.08.004.
42. Martin-Gallausiaux C, Marinelli L, Blottière HM et al. SCFA: mechanisms and functional importance in the gut. Proc Nutr Soc 2021; 80 (1): 37–49. doi: 10.1017/S00296651200 06916.
43. Pluznick JL. Gut microbiota in renal physiology: focus on short-chain fatty acids and their receptors. Kidney Int 2016; 90 (6): 1191–1198. doi: 10.1016/j.kint.2016.06.033.
44. Liu Y, Li YJ, Loh YW et al. Fiber Derived Microbial Metabolites Prevent Acute Kidney Injury Through G-Protein Coupled Receptors and HDAC Inhibition. Front Cell Dev Biol 2021; 9: 648639. doi: 10.3389/fcell.2021. 648639.
45. Yang W, Yu T, Huang X et al. Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity. Nat Commun 2020; 11 (1): 4457. doi: 10.1038/s41467-020-18262-6.
46. Huang W, Zhou L, Guo H et al. The role of short-chain fatty acids in kidney injury induced by gut-derived inflammatory response. Metabolism 2017; 68: 20–30. doi: 10.1016/ j.metabol.2016.11.006.
47. Btaiche IF, Mohammad RA, Alaniz C et al. Amino Acid requirements in critically ill patients with acute kidney injury treated with continuous renal replacement therapy. Pharmacotherapy 2008; 28 (5): 600–613. doi: 10.1592/phco.28.5.600.
48. Chua HR, Puthucheary ZA. Amino Acid Turnover, Protein Metabolism, and Nitrogen Balance in Acute Kidney Injury. In: Ronco C et al (eds). Critical Care Nephrology. Philadelphia: Elsevier 2019: 434–442.
49. Girardot T, Schneider A, Rimmelé T. Blood Purification Techniques for Sepsis and Septic AKI. Semin Nephrol 2019; 39 (5): 505–514. doi: 10.1016/j.semnephrol.2019.06.010.
50. Nadamuni M, Venable AH, Huen SC. When a calorie isn‘t just a calorie: a revised look at nutrition in critically ill patients with sepsis and acute kidney injury. Curr Opin Nephrol Hypertens 2022; 31 (4): 358–366. doi: 10.1097/MNH. 0000000000000801.
51. Chen JH, Chao CT, Huang JW et al. Early elimination of uremic toxin ameliorates AKI-to-CKD transition. Clin Sci (Lond) 2021; 135 (23): 2643–2658. doi: 10.1042/CS20210858.
52. Asai M, Kumakura S, Kikuchi M. Review of the efficacy of AST-120 (KREMEZIN®) on renal function in chronic kidney disease patients. Ren Fail 2019; 41 (1): 47–56. doi: 10.1080/0886022X.2018.1561376.
53. Chávez-Íñiguez JS, Ibarra-Estrada M, Gallardo-González AM et al. Probiotics in septic acute kidney injury, a double blind, randomized control trial. Ren Fail 2023; 45 (2): 2260003. doi: 10.1080/0886022X.2023.2260003.
54. Rossi M, Johnson DW, Morrison M et al. Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial. Clin J Am Soc Nephrol 2016; 11 (2): 223–231. doi: 10.2215/CJN.05240515.
55. McFarlane C, Krishnasamy R, Stanton T et al. Synbiotics Easing Renal Failure by Improving Gut Microbiology II (SYNERGY II): A Feasibility Randomized Controlled Trial. Nutrients 2021; 13 (12): 4481. doi: 10.3390/nu13124481.
56. Fiaccadori E, Sabatino A, Barazzoni R et al. ESPEN guideline on clinical nutrition in hospitalized patients with acute or chronic kidney disease. Clin Nutr 2021; 40 (4): 1644–1668. doi: 10.1016/j.clnu.2021.01.028.
57. Wang J, Jiang L, Ding S et al. Early Enteral Nutrition and Sepsis-Associated Acute Kidney Injury: A Propensity Score Matched Cohort Study Based on the MIMIC-III Database. Yonsei Med J 2023; 64 (4): 259–268. doi: 10.3349/ymj.2022.0276.
58. Reignier J, Boisramé-Helms J, Brisard L et al. Enteral versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel- group study (NUTRIREA-2). Lancet 2018; 391 (10116): 133–143. doi: 10.1016/S0140- 6736 (17) 32146-3.
59. Ni W, Jiao X, Zou Het al. Gut microbiome alterations in ICU patients with enteral nutrition-related diarrhea. Front Microbiol 2022; 13: 1051687. doi: 10.3389/fmicb.2022.1051 687.
ORCID autorů
N. Petejová 0000-0002-5174-5876,
V. Teplan 0000-0001-7717-6686,
A. Martínek 0000-0001-7597-3235,
J. Zadražil 0000-0001-8388-3133.
Doručeno/Submitted: 13. 9. 2024
Přijato/Accepted: 9. 10. 2024
Korespondenční autorka
doc. MUDr. Nadežda Petejová, Ph.D., MSc.
Interní a kardiologická klinika
LF OU a FN Ostrava
17. listopadu 1790/5
708 00 Ostrava 8
petejova@seznam.cz